AMAG Pharmaceuticals (AMAG) & Collegium Pharmaceutical (COLL) Head-To-Head Contrast
AMAG Pharmaceuticals (NASDAQ: AMAG) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.
Earnings & Valuation
This table compares AMAG Pharmaceuticals and Collegium Pharmaceutical’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|AMAG Pharmaceuticals||$532.09 million||0.93||-$2.48 million||($6.08)||-2.31|
|Collegium Pharmaceutical||$1.71 million||268.29||-$94.17 million||($2.98)||-4.73|
AMAG Pharmaceuticals has higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than AMAG Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
AMAG Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of -0.13, suggesting that its share price is 113% less volatile than the S&P 500.
Insider and Institutional Ownership
84.0% of Collegium Pharmaceutical shares are owned by institutional investors. 3.8% of AMAG Pharmaceuticals shares are owned by insiders. Comparatively, 25.8% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares AMAG Pharmaceuticals and Collegium Pharmaceutical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and recommmendations for AMAG Pharmaceuticals and Collegium Pharmaceutical, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AMAG Pharmaceuticals currently has a consensus target price of $24.27, indicating a potential upside of 72.76%. Collegium Pharmaceutical has a consensus target price of $20.00, indicating a potential upside of 41.94%. Given AMAG Pharmaceuticals’ higher possible upside, equities analysts clearly believe AMAG Pharmaceuticals is more favorable than Collegium Pharmaceutical.
AMAG Pharmaceuticals beats Collegium Pharmaceutical on 7 of the 13 factors compared between the two stocks.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.